Musculoskeletal problems in persons with inhibitors: How do we treat?
نویسندگان
چکیده
منابع مشابه
Should we treat pyrexia? And how do we do it?
The concept of pyrexia as a protective physiological response to aid in host defence has been challenged with the awareness of the severe metabolic stress induced by pyrexia. The host response to pyrexia varies, however, according to the disease profile and severity and, as such, the management of pyrexia should differ; for example, temperature control is safe and effective in septic shock but ...
متن کاملHow do we treat people with dementia in Croatia.
The current clinical view on pharmacological treatment and the Croatian reality regarding approved antidementia drugs is presented. Dementia is a syndrome of high incidence and Alzheimer's disease is the most common cause of dementia. New data show that dementia prevalence will nearly double every 20 years, and we believe that current estimated number of persons with dementia (PWD) for Croatia ...
متن کاملHow do we best treat patients with ischemic heart disease?
Despite investigations over several decades, it is still difficult to define an optimal treatment strategy for patients with ischemic heart disease. Some of the many reasons for this dilemma include delayed and highly variable symptomatic presentation, lack of a clear relationship between symptom severity and outcome, a changing population (aging and more women), changing therapies, and a relat...
متن کاملHow do we treat children with severe malaria?
Malaria imposes a profound burden on global public health; over one third of the world’s population (~2 billion people) live in malaria-endemic areas, with ~1 billion people estimated to carry parasites at any one time (Guerin et al., 2002). The greatest burden of malaria falls on sub-Saharan Africa (SSA), where it causes between 200–450 million disease episodes each year and over 1 million dea...
متن کامل“How should we treat older patients with Metastatic Colorectal Cancer, A Review”
Nearly 50 % of newly diagnosed colorectal cancer, affect people over 70 years of age. Inclusion of older patients in clinical trials has been extremely rare. As a result, there is debate on how to manage these patients because it is still unclear how to balance the therapeutic advantages and toxicities. For patients who do not have comorbid conditions, with performance status (P.S.) 0–1, treatm...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Haemophilia
سال: 2012
ISSN: 1351-8216
DOI: 10.1111/j.1365-2516.2012.02874.x